/
CCEL
$3.19-$0.13 (-3.92%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$23.4M
8M shares
52-week range
$2.72 – $5.43
17% from low
Sector
SERVICES-MISC HEALTH & ALLIED SERVICES, NEC
Exchange
XASE
CS
Borrow rate
0.76%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-8.41
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.2M | $31.8M | $31.1M | $28.9M | $30.3M | $31.3M | $32.0M | $31.6M |
| Cost of revenue | $8.5M | $10.0M | $9.7M | $9.0M | $8.8M | $8.4M | $7.9M | $7.4M |
| Gross profit | $20.7M | $21.8M | $21.5M | $19.9M | $21.5M | $22.9M | $24.0M | $24.2M |
| Gross margin | 70.8% | 68.5% | 69.0% | 68.9% | 71.0% | 73.1% | 75.2% | 76.6% |
| R&D | $91.8K | $30.1K | $23.9K | $49.9K | $384.8K | $1.2M | $1.2M | $376.3K |
| Operating income | $5.2M | $5.1M | $7.7M | $4.0M | $4.0M | −$12.3M | $3.5M | $4.8M |
| EBITDA | $5.5M | $5.5M | $7.2M | $5.3M | $6.7M | −$10.4M | $1.4M | $1.1M |
| Net income | −$854.8K | $2.3M | $3.6M | $2.1M | $2.8M | −$9.5M | $402.1K | −$2.4M |
| Net margin | -2.9% | 7.2% | 11.6% | 7.2% | 9.1% | -30.4% | 1.3% | -7.7% |
| EPS (diluted) | -0.11 | 0.27 | 0.45 | 0.25 | 0.33 | -1.14 | 0.05 | -0.30 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $30M | $0.11 | $0.11–$0.11 | 1 |
| 2027 | $28M | $0.02 | $0.02–$0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
www.cryo-cell.com- Employees
- 76
- HQ
- OLDSMAR, FL
Held by traders on TradeandTell
No one on the platform currently holds CCEL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 10,184 | $47.3K |
Insider activity (SEC Form 4)
Dividend history
TTM yield · 20.38% ($0.65/share)
| Ex-date | Per share | Pay date |
|---|---|---|
| 2025-05-21 | $0.1500 | 2025-05-30 |
| 2025-02-14 | $0.2500 | 2025-02-28 |
| 2024-11-15 | $0.2500 | 2024-11-29 |
Recent trades on TradeandTell
No one on the platform has traded CCEL yet.
